title: [Long-term effect of 3-week intravenous alpha-lipoic acid administration in symptomatic diabetic polyneutropathy with clinical manifestations].
abstract: OBJECTIVE
  To estimate the late duration of the effect of 3-week intravenous alpha-lipoic acid (alpha-LA) administration.
  
  
  METHODS
  The study included patients with symptoms of myodiabetic polyneuropathy. The authors studied trends in neuropathic symptoms by the TSS scale and neuropathic deficit by the NIS-LL scale after 3-week intravenous alpha-LA (600 mg/day) administration. Control follow-up visits were made at weeks 8 and 30 of the study.
  
  
  RESULTS
  In alpha-LA-treated patients, the mean TSS score dropped from 9.46 +/- 1.01 to 3.29 +/- 1.49 after intravenous alpha-LA administration and continued to decrease to 260 +/- 1.18 and 4.39 +/- 201 scores at follow-up weeks 8 and 30, respectively. In the placebo group, these were 9.78 +/- 1.23, 6.16 +/- 1.95, 6.52 +/- 1.61, and 736 +/- 1.31 scores at weeks 3, 8, and 30, respectively; p < 0.05). In the alpha-LA group, NIS-LL scores fell from 8.65 +/- 3.46 to 6.01 +/- 3.12 at therapy week 3, to 6.11 +/- 3.36, at week 8, and to 7.68 +/- 3.68 at week 30 and in the placebo group, these decreased from 8.35 +/- 3.84 to 7.81 +/- 3.51, 7.89 +/- 3.72, and 8.32 +/- 3.49 scores at weeks 3, and 8, respectively; p < 0.05).
  
  
  CONCLUSIONS
  . Alleviated neuropathic symptoms persisted within 6 months after 3-week intravenous alpha-LA injection. Reduced neuropathic deficit did within 8 weeks after initiation of alpha-LA therapy.
authors.forename: A S
authors.initials: AS
authors.lastname: Ametov
authors.forename: M V
authors.initials: MV
authors.lastname: Novosadova
authors.forename: A N
authors.initials: AN
authors.lastname: Barinov
authors.forename: R
authors.initials: R
authors.lastname: Samigullin
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Trischler
mesh_terms: D000975:Antioxidants / Q000008:administration & dosage*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D008063:Thioctic Acid / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D008063:Thioctic Acid